COMPARATIVE STUDY BETWEEN DEXMEDETOMIDINE AND FENTANYL AS ADJUVANT TO BUPIVACAINE IN SUPRACLAVICULAR BRACHIAL PLEXUS BLOCK

Main Article Content

Dr. Saleena Beevi C. S.
Dr. Randeep A.M.
Dr. Sudhir N.
Dr. Sunil Kumar T.S.

Keywords

Supraclavicular Brachial Plexus Block, Bupivacaine, Dexmedetomidine, Fentanyl

Abstract

Background: This study was conducted to evaluate the effects of fentanyl and dexmedetomidine as adjuvants to bupivacaine used for supraclavicular brachial plexus block in terms of analgesia, duration of motor block, and sensory and motor block onset times.


Methods: This was a hospital-based prospective comparative study conducted among 70 patients aged 18-60 years belonging to ASA 1 or 2 undergoing upper limb orthopaedic surgeries under supraclavicular brachial plexus block at the Department of Anesthesiology, Government Medical College, Thrissur, Kerala, India, from January 2021 to December 2022 after obtaining clearance from the institutional ethics committee and written informed consent from the study participants.


Results: The statistically significant times for the onset of sensory block were 6.43 ± 1.22 min for the dexmedetomidine group and 10.3 ± 1.25 min for the fentanyl group. The statistically significant motor block onset times were 9.7 ± 0.95 minutes for the dexmedetomidine group and 12.93 ± 1.82 minutes for the fentanyl group. A statistically significant duration of motor block was seen in the dexmedetomidine group (528 ± 48.02 min) and the fentanyl group (460 ± 34.74 min). The duration of sensory block was 538.67 ± 48.62 min in the dexmedetomidine group and 487.33 ± 48.28 min in the fentanyl group, which was statistically significant. The duration of analgesia was 734 ± 34.40 min in the dexmedetomidine group and 650 ± 23.38 min in the fentanyl group, which was statistically significant.


Conclusion: Addition of dexmedetomidine to 0.5% bupivacaine in supraclavicular brachial plexus block significantly reduces the onset of sensory and motor block and prolongs the duration of sensory and motor block and the duration of analgesia compared to fentanyl with 0.5% bupivacaine.

Abstract 150 | pdf Downloads 111

References

1. Hashim RM, Hassan RM. The efficacy of adjuvants to bupivacaine in ultrasound-guided supraclavicular block: a comparative study between dexmedetomidine, ketamine, and fentanyl. Ain-Shams J Anesthesiol 2019;11(1):19.
2. Yang CW, Cho CK, Kwon HU, Roh JY, Heo YM, Ahn SM. Ultrasound-guided supraclavicular brachial plexus block in pediatric patients -a report of four cases-. Korean J Anesthesiol 2010;59(Suppl):S90.
3. Gertler R, Brown HC, Mitchell DH, Silvius EN. Dexmedetomidine: A novel sedative-analgesic agent. Bayl Univ Med Cent Proc 2001;14(1):13-21.
4. Hamed MA, Ghaber S, Reda A. Dexmedetomidine and fentanyl as an adjunct to bupivacaine 0.5% in supraclavicular nerve block: a randomized controlled study. Anesth Essays Res 2018;12(2):475-9.
5. Rao S, Rajan N. Dexmedetomidine as an Adjunct for Regional Anesthetic Nerve Blocks. Curr Pain Headache Rep 2021;25(2):8.
6. Song L, Tan S, Chen Q, Li H. Effect of fentanyl as an adjuvant to brachial plexus block for upper extremity surgeries: a systematic review and meta-analysis of RCTs. Pain Res Manag 2022;2022:1-13.
7. Dharmarao PS, Holyachi R. Comparative study of the efficacy of dexmedetomidine and fentanyl as adjuvants to ropivacaine in ultrasound-guided supraclavicular brachial plexus block. Turk J Anesth Reanim 2018;46(3)208-13.
8. Memis D, Turan A, Karamanloglu B, Pamukçu Z, Kurt I. Adding dexmedetomidine to lidocaine for intravenous regional anesthesia. Anesth Analg 2004;98(3):835-40.